At the forefront of a revolution in cancer treatment
Chimeric Antigen Receptor (CAR) T cell therapies have been shown to be effective in some hematological malignancies and may have wide applications as a cancer treatment, with the potential for cure in some patients. Autolus uses its rich technology toolbox and expertise to refine and tailor its therapeutic candidates to tackle the indication of interest.
Autolus is a leader in T cell programming, underpinning the broad technology toolbox and manufacturing technology. Autolus is developing cancer therapies which we believe will offer patients substantial benefits over the existing standard of care.
A strong investor base
Autolus has secured funds for the development and filing of it's lead product, in addition to preparation for commercialization and the initial manufacturing infrastructure build.
Autolus is focused on developing potentially curative therapies for areas of high unmet need, as well as striving to deliver value for its shareholders.